COMPOUNDS / PSYCHIATRIC / BACLOFEN
PSYCHIATRIC

BACLOFEN

MEDIUM RISK
BEST FOR:Spasticity●●●●●●●●●○9/10
BACLOFEN · LIORESAL · GABLOFEN · KEMSTRO · BETA-(4-CHLOROPHENYL)-GABA · Β-(4-CHLOROPHENYL)-Γ-AMINOBUTYRIC ACID
GABA-B AgonistMuscle RelaxantAntispasmodicAlcohol WithdrawalPrescription

GABA-B agonist used for spasticity and off-label for alcohol use disorder.

ROUTE / DOSAGE
LOW5-10mg
STANDARD20-50mg
HIGH50-100mg
Note: Doses up to 150-300mg/day used off-label for alcohol craving suppression under medical supervision
CYCLE
Divided doses 3-4x daily continuous infusion for intrathecal
BIOAVAILABILITY
~95% oral
ACTIVE DURATION
4-8h (subjective)
STORAGE
Room temperature dry away from light intrathecal formulations require sterile handling
HALF-LIFE
2-6.8h (plasma)
DURATION BREAKDOWN
Total4-8h
Onset30-75min
Come up1-1.5h
Peak2-3h
Offset2-4h
After effects2-6h
Duration varies by route, dose, and individual. Source: community reports.
§ 01 — EFFECTS
6 documented
Muscle relaxation
Spasticity reduction
Sedation
Reduced alcohol craving
Dizziness
Somnolence
§ 02 — RISKS
Abrupt withdrawal can cause seizures, hallucinations, and life-threatening rebound spasticity
Respiratory depression especially with CNS depressants or intrathecal overdose
Baclofen-induced psychosis at therapeutic doses
Increased depression symptoms in AUD treatment
Sedation, vertigo, and paraesthesia
Intrathecal pump complications including infection, catheter failure, and overdose
§ 03 — INTERACTIONS
No interaction with your stack
VIEW STACK
AVOID · DANGEROUS
Dissociatives
Stimulants
Alcohol
Benzodiazepines
Barbiturates
GHB
GBL
Methaqualone
Opioids
Depressants
§ 04 — SCIENCE

Baclofen is FDA-approved for spasticity and is the only approved GABA-B agonist. Intrathecal baclofen is well-established for severe spasticity of spinal origin. For alcohol use disorder (AUD), evidence is mixed: a Cochrane review found no significant difference vs placebo for primary outcomes, while observational studies using tailored doses report good effectiveness. A meta-analysis of 14 RCTs found only a small, non-significant superiority over placebo. High doses (up to 300mg/day) are used in France for AUD but carry increased risk of severe adverse effects including sedation, respiratory depression, and psychosis.

§ 06 — SOURCES
[1]
PubMed PMID 38266071
pubmed.ncbi.nlm.nih.gov ↗
[2]
PubMed PMID 35314493
pubmed.ncbi.nlm.nih.gov ↗
[3]
PubMed PMID 32436697
pubmed.ncbi.nlm.nih.gov ↗
[4]
PubMed PMID 30484285
pubmed.ncbi.nlm.nih.gov ↗
[5]
PubMed PMID 30898271
pubmed.ncbi.nlm.nih.gov ↗
[6]
PubMed PMID 29888478
pubmed.ncbi.nlm.nih.gov ↗
[7]
PubMed PMID 8143075
pubmed.ncbi.nlm.nih.gov ↗
[8]
PubMed PMID 17047139
pubmed.ncbi.nlm.nih.gov ↗
[9]
PsychonautWiki - Baclofen
psychonautwiki.org ↗
Disclaimer. Protokol.wiki is an informational reference. Nothing on this site is medical advice. Compounds listed may be unapproved, unregulated, or illegal in your jurisdiction. Consult a licensed physician before use. Data compiled from peer-reviewed literature.
METHODOLOGYCONTRIBUTECONTACT